Impact of treatments on fatigue in axial spondyloarthritis: a systematic review and meta-analysis (2025)
https://pubmed.ncbi.nlm.nih.gov/39388256/

Reducing diagnostic delay in axial spondyloarthritis (2025)
https://pubmed.ncbi.nlm.nih.gov/39900198/

Correspondence on ‘The Assessment of SpondyloArthritis International Society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis’ by Poddubnyy D, et al (2025)
https://pubmed.ncbi.nlm.nih.gov/40133191/

Muscle in axial spondyloarthritis: Culprit or victim? (2025)
https://pubmed.ncbi.nlm.nih.gov/40185463/

Comparison of Sacroiliac CT Findings in Patients with Skin Psoriasis, Without Rheumatological Manifestations: A Retrospective Observational Study (2025)
https://pubmed.ncbi.nlm.nih.gov/40377409/

Early peripheral psoriatic arthritis: Baseline features of the first 186 patients in the French Nationwide APACHE Cohort (2025)
https://pubmed.ncbi.nlm.nih.gov/40441347/

Residual disease in axial spondyloarthritis. Facts and issues (2025)
https://pubmed.ncbi.nlm.nih.gov/40609630/

When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it? (2025)
https://pubmed.ncbi.nlm.nih.gov/40681212/

Navigating clinical research challenges in spondyloarthritis: Insights from the French Spondyloarthritis Taskforce (FAST) (2025)
https://pubmed.ncbi.nlm.nih.gov/40935123/

IL-33 in Spondyloarthritis, the missing key (2025)
https://pubmed.ncbi.nlm.nih.gov/41135784/

The changing face of axial spondyloarthritis over the last 25 years (2025)
https://pubmed.ncbi.nlm.nih.gov/41241313/

Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis (2024)
https://pubmed.ncbi.nlm.nih.gov/37678285/

Initial C-reactive protein level: Discriminating between anti-TNF and anti-IL-17 agents as the first biologic treatment for axial spondyloarthritis? (2024)
https://pubmed.ncbi.nlm.nih.gov/37977524/

Effects of disease-modifying anti-rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: a systematic review and meta-analysis (2024)
https://pubmed.ncbi.nlm.nih.gov/38158505/

Ten-year clinical outcome of recent-onset axial spondyloarthritis: Results from the DESIR inception Cohort (2024)
https://pubmed.ncbi.nlm.nih.gov/38163581/

Sacroiliac radiographic progression over 10 years in axSpA: data from the DESIR inception cohort (2024)
https://pubmed.ncbi.nlm.nih.gov/38423758/

Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study (2024)
https://pubmed.ncbi.nlm.nih.gov/38428974/

Axial spondyloarthritis and inflammatory bowel disease: Therapeutic implications (2024)
https://pubmed.ncbi.nlm.nih.gov/38479580/

Can we consider a pre-clinical state of axial spondyloarthritis? (2024)
https://pubmed.ncbi.nlm.nih.gov/38582360/

Standardized reporting for systematic global evaluation of axial spondyloarthritis: An evidence-based and consensus-driven initiative (2024)
https://pubmed.ncbi.nlm.nih.gov/38604594/

Unmet needs in axial spondyloarthritis. Proceedings of the French spondyloarthritis taskforce workshop (2024)
https://pubmed.ncbi.nlm.nih.gov/38795763/

Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort (2024)
https://pubmed.ncbi.nlm.nih.gov/39043614/

Evolution of FIB-4 score in SpA and PsA patients taking anti-TNF or anti-IL17 (2024)
https://pubmed.ncbi.nlm.nih.gov/39084400/

Rheumatol Ther . 2024 Oct;11(5):1065-1079. doi: 10.1007/s40744-024-00704-y. Epub 2024 Aug 12. Treatment with Targeted Therapy in Patients with Psoriatic Arthritis and Inadequate Response to Methotrexate: Proposal for a Rational Strategy (2024)
https://pubmed.ncbi.nlm.nih.gov/39134832/

Rotation or change of biotherapy after TNF blocker treatment failure for axial spondyloarthritis: the ROC-SpA study, a randomised controlled study protocol (2024)
https://pubmed.ncbi.nlm.nih.gov/39260856/

Difficult-to-Treat Axial Spondyloarthritis: A New Challenge (2024)
https://pubmed.ncbi.nlm.nih.gov/39388075/

Séraphin (1747-1800), “the facetious hunchback”: How ankylosing spondylitis contributed to the success of his shadow puppet theatre (2024)
https://pubmed.ncbi.nlm.nih.gov/39535600/

Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study (2023)
https://pubmed.ncbi.nlm.nih.gov/36752498/

Influence of Sex on Early Axial Spondyloarthritis: A Six-Year Longitudinal Analysis From a Large National Cohort (2023)
https://pubmed.ncbi.nlm.nih.gov/36785996/

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries (2023)
https://pubmed.ncbi.nlm.nih.gov/36787993/

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA) (2023)
https://pubmed.ncbi.nlm.nih.gov/36921980/

Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis (2023)
https://pubmed.ncbi.nlm.nih.gov/37678285/

Comparison of sacroiliac CT findings in patients with and without psoriatic arthritis: results of the CASIPSA Study (2023)
https://pubmed.ncbi.nlm.nih.gov/37252815/

Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study. Rheumatology (Oxford). 2023 Oct 3;62(10):3317-3322. doi: 10.1093/rheumatology/kead072. PMID: 36752498. (2023)
https://pubmed.ncbi.nlm.nih.gov/36752498/

Influence of Sex on Early Axial Spondyloarthritis: A Six-Year Longitudinal Analysis From a Large National Cohort (2023)
https://pubmed.ncbi.nlm.nih.gov/36785996/

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries (2023)
https://pubmed.ncbi.nlm.nih.gov/36787993/

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA) (2023)
https://pubmed.ncbi.nlm.nih.gov/36921980/

Psoriatic dactylitis (2023)
https://pubmed.ncbi.nlm.nih.gov/36963750/

Comparison of sacroiliac CT findings in patients with and without psoriatic arthritis: results of the CASIPSA Study (2023)
https://pubmed.ncbi.nlm.nih.gov/37252815/

Comparison of sacroiliac CT findings in patients with and without ankylosing spondylitis aged over 50 years (2023)
https://pubmed.ncbi.nlm.nih.gov/37863967/

Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study (2023)
https://pubmed.ncbi.nlm.nih.gov/37996127/

Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort (2022)
https://pubmed.ncbi.nlm.nih.gov/34270707/

Tight control and treat-to-target in axial spondyloarthritis. Where are we? (2022)
https://pubmed.ncbi.nlm.nih.gov/34506936/

Exploring remission concept in axial spondyloarthritis through the perception of rheumatologists using vignettes and priority ratings (2022)
https://pubmed.ncbi.nlm.nih.gov/34528070/

Differences in distribution by department of prevalence and incidence of spondyloarthritis and inflammatory bowel diseases declared to the French National Health Insurance and their evolution between 2008 and 2018 (2022)
https://pubmed.ncbi.nlm.nih.gov/34648939/

2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis (2022)
https://pubmed.ncbi.nlm.nih.gov/35038574/

Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6 years (2022)
https://pubmed.ncbi.nlm.nih.gov/35091462/

Systematic assessment of heart valves and cardiac function by echocardiography in axial spondyloarthritis: A systematic review and meta-analysis (2022)
https://pubmed.ncbi.nlm.nih.gov/35259478/

Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France (2022)
https://pubmed.ncbi.nlm.nih.gov/35301266/

Axial psoriatic arthritis: New entity or clinical form only? (2022)
https://pubmed.ncbi.nlm.nih.gov/35577051/

Subchondral bone attenuation coefficient utility of the sacroiliac margins to differentiate spondyloarthritis and osteitis condensans ilii (2022)
https://pubmed.ncbi.nlm.nih.gov/35580924/

Development and Validation of a Self-Administered Questionnaire Measuring Essential Knowledge in Patients With Axial Spondyloarthritis (2022)
https://pubmed.ncbi.nlm.nih.gov/35840152/

World mortality of ankylosing spondylitis, psoriatic arthritis and inflammatory bowel disease in 2015 and its evolution from 2001 to 2015 (2022)
https://pubmed.ncbi.nlm.nih.gov/35940547/

Frequency and anatomic distribution of magnetic resonance imaging lesions in the sacroiliac joints of spondyloarthritis and non-spondyloarthritis patients (2022)
https://pubmed.ncbi.nlm.nih.gov/36081745/

Is the Difficult-to-Treat (D2T) concept applicable to axial spondyloarthritis? (2022)
https://pubmed.ncbi.nlm.nih.gov/36528335/

Is psoriatic arthritis doomed to disappear? (2022)
https://pubmed.ncbi.nlm.nih.gov/36404487/

Intestinal permeability in spondyloarthritis and rheumatoid arthritis: A systematic review of the literature. Semin Arthritis Rheum. 2021 Aug;51(4):712-718. doi: 10.1016/j.semarthrit.2021.04.015. Epub 2021 May 6. PMID: 34139524. (2021)
https://pubmed.ncbi.nlm.nih.gov/34139524/

Uveitis occurrence in early inflammatory back pain. Five years data from the prospective French nationwide DESIR cohort (2020)
https://pubmed.ncbi.nlm.nih.gov/33166730/

Can SARS-CoV-2 trigger reactive arthritis? (2020)
https://pubmed.ncbi.nlm.nih.gov/33127461/

ASAS Health Index: The “All in One” for Spondyloarthritis Evaluation? (2020)
https://pubmed.ncbi.nlm.nih.gov/33004479/

Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis. (2020)
https://pubmed.ncbi.nlm.nih.gov/32635788/

From observational studies to personalized treatment in spondylarthritis: focus on IL-17 inhibition. (2020)
https://pubmed.ncbi.nlm.nih.gov/32529902/

Toward a tailored therapeutic prescription for patients with axial spondyloarthritis. (2020)
https://pubmed.ncbi.nlm.nih.gov/32534199/

Low Back Pain and Sacroiliitis on Cross-Sectional Abdominal Imaging for Axial Spondyloarthritis Diagnosis in Inflammatory Bowel Diseases. (2020)
https://pubmed.ncbi.nlm.nih.gov/32999885/

Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. (2020)
https://pubmed.ncbi.nlm.nih.gov/32521324/

Share Reactive Arthritis: Treatment Challenges and Future Perspectives. (2020)
https://pubmed.ncbi.nlm.nih.gov/32458153/

Data to be collected for an optimal management of axial spondyloarthritis in daily practice: Proposal from evidence-based and consensual approaches. (2020)
https://pubmed.ncbi.nlm.nih.gov/32428691/

Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review. (2020)
https://pubmed.ncbi.nlm.nih.gov/32306777/

Are the recommendations for the use of anti-TNF drugs during axial spondyloarthritis relevant for non-radiographic forms? (2020)
https://pubmed.ncbi.nlm.nih.gov/32147568/

Ultrasonographic Involvement of the anterior chest wall in Spondyloarthritis: Factors associated with 5-years structural progression. A prospective study in 58 patients. (2020)
https://pubmed.ncbi.nlm.nih.gov/32147567/

5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort. (2020)
https://pubmed.ncbi.nlm.nih.gov/32396521/

Dactylitis in early spondyloarthritis. Data from the prospective French national cohort DESIR. (2020)
https://pubmed.ncbi.nlm.nih.gov/31958574/

Cardiovascular risk in psoriatic arthritis, a narrative review. (2020)
https://pubmed.ncbi.nlm.nih.gov/31958573/

Effects of anti-IL-23 and anti-IL-17: The hidden side of spondyloarthritis polymorphism? (2020)
https://pubmed.ncbi.nlm.nih.gov/31324528/

Local sacroiliac injections in the treatment of spondyloarthritis. What is the evidence? (2020)
https://pubmed.ncbi.nlm.nih.gov/31216488/

Effect of Gut Involvement in Patients with High Probability of Early Spondyloarthritis: Data from the DESIR Cohort. (2020)
https://pubmed.ncbi.nlm.nih.gov/31154418/

New targeted therapies in spondyloarthritis: what are the limits? (2019)
https://pubmed.ncbi.nlm.nih.gov/30943857/

Clinical peripheral enthesitis in the DESIR prospective longitudinal axial spondyloarthritis cohort. (2019)
https://pubmed.ncbi.nlm.nih.gov/30620273/

Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. (2019)
https://pubmed.ncbi.nlm.nih.gov/30500270/

Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review. (2019)
https://pubmed.ncbi.nlm.nih.gov/30328022/

Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus. (2019)
https://pubmed.ncbi.nlm.nih.gov/30243782/

Aerobic exercise for axial spondyloarthritis – its effects on disease activity and function as compared to standard physiotherapy: A systematic review and meta-analysis. (2019)
https://pubmed.ncbi.nlm.nih.gov/30187695/

Vascular involvement in axial spondyloarthropathies. (2019)
https://pubmed.ncbi.nlm.nih.gov/29787813/

Increase In Il-31 Serum Levels Is Associated With Reduced Structural Damage In Early Axial Spondyloarthritis. (2018)
https://pubmed.ncbi.nlm.nih.gov/29769586/

2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. (2018)
https://pubmed.ncbi.nlm.nih.gov/29407043/

Disease activity in ankylosing spondylitis: the global therapeutic target. (2018)
https://pubmed.ncbi.nlm.nih.gov/29247127/

Spondyloarthritis: An expanding cast of cellular actors. (2018)
https://pubmed.ncbi.nlm.nih.gov/28495522/

Spondyloarthritis: Harlequin or Chameleon? (2017)
https://pubmed.ncbi.nlm.nih.gov/28864662/

Deaths Associated with Ankylosing Spondylitis in France from 1969 to 2009. (2017)
https://pubmed.ncbi.nlm.nih.gov/28298562/